| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11617713 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US11628139 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
Kloxxado is owned by Hikma.
Kloxxado contains Naloxone Hydrochloride.
Kloxxado has a total of 5 drug patents out of which 0 drug patents have expired.
Kloxxado was authorised for market use on 29 April, 2021.
Kloxxado is available in spray;nasal dosage forms.
Kloxxado can be used as use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
The generics of Kloxxado are possible to be released after 26 August, 2034.
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY;NASAL
KLOXXADO family patents
